3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
4
Breast
4
Thoracic
2
Lymphoid
2
Gynecologic
2
CNS
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Head & Neck
1
Endocrine
1
Conditions
Ovarian Neoplasms
6
Breast Neoplasms
6
Endometrial Neoplasms
4
Fallopian Tube Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Mesothelioma
1
Lymphoma
1
Leukemia
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Digestive System Neoplasms
1
Carcinosarcoma
1
Breast Diseases
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
28
Carboplatin
28
pembrolizumab
25
Bevacizumab
14
liposomal doxorubicin
12
Cisplatin
11
Gemcitabine
10
Radiotherapy
8
Drug Therapy
8
Cyclophosphamide
8
Blood Specimen Collection
8
Topotecan
7
Nivolumab
7
olaparib
6
Doxorubicin
6
niraparib
5
Therapeutics
5
Dexamethasone
5
pertuzumab
4
pazopanib
4
lenvatinib
4
fludarabine
4
cemiplimab
4
atezolizumab
4
Trastuzumab
4
Surveys and Questionnaires
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Fulvestrant
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
ribociclib
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts